These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 22629478

  • 1. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [Abstract] [Full Text] [Related]

  • 2. Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.
    Ghosh S, Verma A, Kumar D, Deep DK, Ramesh V, Salotra P, Singh R.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0402623. PubMed ID: 38712926
    [Abstract] [Full Text] [Related]

  • 3. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J, Madhubala R, Singh S.
    Parasitol Res; 2013 Mar 04; 112(3):1001-9. PubMed ID: 23242321
    [Abstract] [Full Text] [Related]

  • 4. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
    Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, Sundar S, Ramesh V, Dujardin JC, Salotra P.
    PLoS Negl Trop Dis; 2017 Jun 04; 11(6):e0005641. PubMed ID: 28575060
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V, Dixit KK, Sharma N, Singh R, Salotra P.
    J Infect Dis; 2020 Feb 03; 221(4):608-617. PubMed ID: 31854451
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
    Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC.
    Clin Infect Dis; 2013 Jun 03; 56(11):1530-8. PubMed ID: 23425958
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
    Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S.
    Am J Trop Med Hyg; 2013 Oct 03; 89(4):750-4. PubMed ID: 23980130
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS, Kumar A, Hossain AFMA, Mahshin M, Sharma A, Hossain MA, Sharma V, Haque R, Shamsuzzaman AKM, Maruf S, Ghosh P, Ahuja V, Mondal D.
    Infect Dis Poverty; 2018 Aug 13; 7(1):80. PubMed ID: 30099967
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
    Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P.
    Parasitol Res; 2012 Oct 13; 111(4):1559-68. PubMed ID: 22752721
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
    Moulik S, Chaudhuri SJ, Sardar B, Ghosh M, Saha B, Das NK, Chatterjee M.
    Clin Infect Dis; 2018 Jan 18; 66(3):404-410. PubMed ID: 29020350
    [Abstract] [Full Text] [Related]

  • 18. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.
    Trop Med Int Health; 2012 Nov 18; 17(11):1345-8. PubMed ID: 22882665
    [Abstract] [Full Text] [Related]

  • 19. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
    Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P.
    PLoS Negl Trop Dis; 2015 Nov 18; 9(10):e0004093. PubMed ID: 26492039
    [Abstract] [Full Text] [Related]

  • 20. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D, Mukherjee S, Ghosh S, Roy S, Saha B, Das NK, Chatterjee M.
    Int J Dermatol; 2016 May 18; 55(5):e250-5. PubMed ID: 26536363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.